Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Évaluation de la suspension inhalée TQC3721 chez les patients atteints de bronchopneumopathie chronique obstructive modérée à sévère

24 septembre 2026 mis à jour par: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Évaluation du profil de sécurité dans une étude de cohorte de la suspension inhalée de TQC3721 chez des patients atteints de bronchopneumopathie chronique obstructive modérée à sévère

To evaluate the safety of inhaled TQC3721 Suspension in patients with moderate to severe Chronic Obstructive Pulmonary Disease

Aperçu de l'étude

Statut

Recrutement

Les conditions

Intervention / Traitement

Type d'étude

Interventionnel

Inscription (Estimé)

800

Phase

  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: Weimin Li, Doctor
  • Numéro de téléphone: 028-85423998
  • E-mail: weimin003@163.com

Lieux d'étude

    • Anhui
      • Chizhou, Anhui, Chine, 247000
        • Recrutement
        • Chizhou People's Hospital
        • Contact:
      • Hefei, Anhui, Chine, 238000
        • Recrutement
        • Chaohu Hospital of Anhui Medical University
        • Contact:
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, Chine, 404000
        • Recrutement
        • Chongqing University Three Gorges Hospital
        • Contact:
      • Chongqing, Chongqing Municipality, Chine, 400054
        • Recrutement
        • Peolpe's Hospital Of Chongqing Banan District
        • Contact:
      • Chongqing, Chongqing Municipality, Chine, 408099
        • Recrutement
        • Fuling Hospital Affiliated to Chongqing University
        • Contact:
          • Qianli Ma, Doctor
          • Numéro de téléphone: 13996030312
          • E-mail: cqmql@163.com
    • Fujian
      • Zhangzhou, Fujian, Chine, 363000
        • Recrutement
        • Zhangzhou Municipal Hospital of Fujian Province
        • Contact:
    • Gansu
      • Lanzhou, Gansu, Chine, 730000
        • Recrutement
        • The First Hospital of Lanzhou University
        • Contact:
      • Lanzhou, Gansu, Chine, 730099
        • Recrutement
        • Gansu Provincial Hospital
        • Contact:
        • Contact:
    • Guangdong
      • Foshan, Guangdong, Chine, 528300
        • Recrutement
        • The Eighth Affiliated Hospital of Southern Medical University (The First people's Hospital of Shunde )
        • Contact:
      • Shenzhen, Guangdong, Chine, 518000
        • Recrutement
        • Peking University Shenzhen Hospital
        • Contact:
    • Guizhou
      • Guiyang, Guizhou, Chine, 550000
        • Recrutement
        • Guizhou Provincial People's Hospital
        • Contact:
          • Xianwei Ye, Doctor
          • Numéro de téléphone: 18798619198
          • E-mail: yxw1205@163.com
    • Hainan
      • Haikou, Hainan, Chine, 570102
        • Recrutement
        • The First Affiliated Hospital of Hainan Medical University
        • Contact:
          • Huaping Huang, Doctor
          • Numéro de téléphone: 13138997957
          • E-mail: 1297034257@qq.com
    • Hebei
      • Langfang, Hebei, Chine, 65000
        • Recrutement
        • Hebei PetroChina Central Hospital
        • Contact:
      • Xingtai, Hebei, Chine, 054000
        • Recrutement
        • People Hospital of Xingtai
        • Contact:
    • Heilongjiang
      • Daqing, Heilongjiang, Chine, 163000
        • Recrutement
        • Daqing Longnan Hospital
        • Contact:
          • Jinli Liu, Bachelor
          • Numéro de téléphone: 18845980808
          • E-mail: 969089802@qq.com
      • Qiqihar, Heilongjiang, Chine, 161005
        • Recrutement
        • Qiqihar First Hospital
        • Contact:
          • Jian Ding, Master
          • Numéro de téléphone: 15645231111
          • E-mail: 252518789@qq.com
    • Henan
      • Jiaozuo, Henan, Chine, 454001
        • Recrutement
        • Jiaozuo Second People's Hospital
        • Contact:
      • Puyang, Henan, Chine, 457001
        • Recrutement
        • Puyang Oilfield General Hospital
        • Contact:
          • Faming Yu, Bachelor
          • Numéro de téléphone: 13700802698
          • E-mail: mingfayu@126.com
      • Shangqiu, Henan, Chine, 476100
        • Recrutement
        • The First People's Hospital of Shangqiu
        • Contact:
    • Hubei
      • Yichang, Hubei, Chine, 443003
        • Recrutement
        • Yichang Central People's Hospital
        • Contact:
          • Fanjun Zeng, Master
          • Numéro de téléphone: 13997672619
          • E-mail: 438864941@qq.com
    • Hunan
      • Changsha, Hunan, Chine, 410001
        • Recrutement
        • Hunan Provincial People's Hospital
        • Contact:
          • Nian Liu, Master
          • Numéro de téléphone: 13975188303
          • E-mail: 19781138@qq.com
      • Yongzhou, Hunan, Chine, 425002
        • Recrutement
        • The Central Hospital of Yongzhou
        • Contact:
    • Inner Mongolia
      • Chifeng, Inner Mongolia, Chine, 24000
        • Recrutement
        • Chifeng Municipal Hospital
        • Contact:
    • Jiangsu
      • Wuxi, Jiangsu, Chine, 214001
        • Recrutement
        • The Fifth People's Hospital of Wuxi
        • Contact:
      • Wuxi, Jiangsu, Chine, 214400
        • Recrutement
        • Jiangyin Hospital of Traditional Chinese Medicine
        • Contact:
          • Xiaodong Hu, Bachelor
          • Numéro de téléphone: 17768318018
          • E-mail: 30223273@qq.com
      • Xuzhou, Jiangsu, Chine, 221009
        • Pas encore de recrutement
        • Xuzhou Central Hospital
        • Contact:
          • Yanmin Wu, Master
          • Numéro de téléphone: 18952170625
          • E-mail: wymin666@163.com
      • Yangzhou, Jiangsu, Chine, 225001
        • Recrutement
        • Subei People's Hospital of Jiangsu province
        • Contact:
      • Yixing, Jiangsu, Chine, 225000
        • Recrutement
        • Yixing People's Hospital
        • Contact:
          • Jianzhong Jiang, Bachelor
          • Numéro de téléphone: 15906156662
          • E-mail: staff290@yxph.com
        • Contact:
    • Jiangxi
      • Nanchang, Jiangxi, Chine, 330006
        • Recrutement
        • The First Affiliated Hospital of Nanchang University
        • Contact:
          • Wei Zuo, Master
          • Numéro de téléphone: 15879098337
          • E-mail: 11545394@qq.com
      • Nanchang, Jiangxi, Chine, 330006
        • Recrutement
        • Jiangxi Provincial People's Hospital
        • Contact:
          • Zuke Xiao, Bachelor
          • Numéro de téléphone: 13970010036
          • E-mail: Xiaozuke@126.com
    • Jilin
      • Changchun, Jilin, Chine, 130000
        • Recrutement
        • The first hospital of Jilin University
        • Contact:
    • Liaoning
      • Dalian, Liaoning, Chine, 116000
        • Recrutement
        • Central Hospital of Dalian University of Technology
        • Contact:
      • Shenyang, Liaoning, Chine, 110021
        • Recrutement
        • Shengjing Hospital of China Medical University
        • Contact:
    • Neimenggu
      • Hohhot, Neimenggu, Chine, 10000
        • Recrutement
        • Inner Mongolia Medical University Affiliated Hospital
        • Contact:
    • Shandong
      • Binzhou, Shandong, Chine, 256610
        • Recrutement
        • Binzhou People's Hospital
        • Contact:
      • Heze, Shandong, Chine, 274031
        • Recrutement
        • Heze Municipal Hospital
        • Contact:
          • Xunchao Liu, Doctor
          • Numéro de téléphone: 13184069557
          • E-mail: lxunchao@163.com
      • Jining, Shandong, Chine, 272029
        • Recrutement
        • Affiliated Hospital of Jining Medical University
        • Contact:
      • Weifang, Shandong, Chine, 261000
        • Recrutement
        • Weifang NO.2 People's Hospital
        • Contact:
      • Yantai, Shandong, Chine, 264099
        • Recrutement
        • Yantai Yuhuangding Hospital
        • Contact:
          • Shenchun Zhou, Master
          • Numéro de téléphone: 18660515179
          • E-mail: ytbqjwhx@sina.com
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Chine, 200023
        • Recrutement
        • Ruijin Hospital, Shanghai Jiaotong University School of Medicine
        • Contact:
    • Shanxi
      • Baoji, Shanxi, Chine, 721008
        • Recrutement
        • Baoji Central Hospital
        • Contact:
      • Changzhi, Shanxi, Chine, 46000
        • Recrutement
        • Changzhi People's Hospital
        • Contact:
      • Xianyang, Shanxi, Chine, 712000
        • Recrutement
        • Yan'an University Xianyang Hospital
        • Contact:
          • Jianhou Jia, Bachelor
          • Numéro de téléphone: 13892007197
          • E-mail: jjh20@126.com
      • Xi’an, Shanxi, Chine, 710100
        • Recrutement
        • Xi'an International Medical Center Hospital
        • Contact:
      • Yangquan, Shanxi, Chine, 45000
        • Recrutement
        • Yangquan coal Industry(Group) General Hospital
        • Contact:
          • Ruibin Guo, Bachelor
          • Numéro de téléphone: 13935324120
          • E-mail: grb8888@126.com
    • Sichuan
      • Chengdu, Sichuan, Chine, 610044
        • Recrutement
        • West China Hospital of Sichuan University
        • Contact:
      • Chengdu, Sichuan, Chine, 610000
        • Recrutement
        • The First Affiliated Hospital of Chengdu Medical College
        • Contact:
      • Mianyang, Sichuan, Chine, 621000
        • Recrutement
        • Mianyang Hospital of Traditional Chinese Medicine
        • Contact:
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Chine, 300052
        • Recrutement
        • Tianjin Medical University General Hospital
        • Contact:
      • Tianjin, Tianjin Municipality, Chine, 300140
        • Recrutement
        • Tianjin 4th Center Hospital
        • Contact:
    • Xinjiang
      • Shihezi, Xinjiang, Chine, 832008
        • Recrutement
        • The First Affiliated Hospital of Shihezi University
        • Contact:
    • Zhejiang
      • Jinhua, Zhejiang, Chine, 321000
        • Recrutement
        • Jinhua municipal central hospital
        • Contact:
      • Jinhua, Zhejiang, Chine, 322100
        • Recrutement
        • Dongyang People's Hospital
        • Contact:
      • Wenzhou, Zhejiang, Chine, 325000
        • Recrutement
        • The Second Affiliated Hospital of Wenzhou Medical University
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

40 ans à 80 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

Cohort A:

  • Subjects who have completed the TQC3721-III-01 clinical trial, demonstrated good medication compliance during the 24-week treatment period as required by the protocol (with no major protocol deviations related to medication compliance), and experienced no treatment-related SAEs.
  • Sign the informed consent form and fully understand the trial content, procedures, and potential adverse reactions.
  • Willing and able to comply with the trial arrangements and to use the nebulizer correctly.
  • Subjects have no pregnancy plans from screening until at least 1 month after the last dose of the investigational drug and voluntarily adopt effective contraception measures.
  • Patients with a clear clinical history and related symptoms of COPD (meeting the diagnostic criteria for COPD as outlined in the Chinese Guidelines for the Diagnosis and Management of Chronic Obstructive Pulmonary Disease (2021 Revised Edition)).

Cohort B:

  • Sign the informed consent form prior to screening and fully understand the trial content, procedures, and potential adverse reactions.
  • Willing and able to comply with the trial arrangements and to use the nebulizer correctly.
  • Aged between 40 and 80 years (inclusive), both male and female subjects are eligible.
  • Subjects have no pregnancy plans from screening until at least 1 month after the last dose of the investigational drug and voluntarily adopt effective contraception measures.
  • Patients with a clear clinical history and related symptoms of COPD prior to screening (meeting the diagnostic criteria for COPD as outlined in the Chinese Guidelines for the Diagnosis and Management of Chronic Obstructive Pulmonary Disease (2021 Revised Edition)).
  • At the screening visit (V1), post-bronchodilator (salbutamol 4 puffs) lung function shows an FEV1/FVC ratio <0.7, and 30% predicted value ≤ FEV1 < 80% predicted value.
  • A modified Medical Research Council (mMRC) dyspnea scale score of ≥1 at screening (V1).
  • Subjects on single or dual bronchodilator background therapy (with or without an Inhaled Corticosteroid component) must have been on stable treatment for at least 2 weeks prior to screening.
  • Clinically stable COPD (no moderate or severe COPD exacerbations) within 4 weeks prior to the screening visit (Visit V1).
  • Smoking history of ≥10 pack-years (pack-years: packs per day * years of smoking, e.g., 1 pack of 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years) OR a history of exposure to biomass fuels.

Exclusion Criteria:

Cohort A:

  • History of life-threatening chronic obstructive pulmonary disease (COPD) (e.g., prior intensive care unit admission or requiring intubation).
  • Presence of other clinically significant respiratory diseases, such as alpha-1 antitrypsin deficiency, active pulmonary infection, bronchiectasis, interstitial lung disease, pulmonary arterial hypertension, or asthma.
  • Any other systemic disease deemed by the investigator to be clinically significant and not adequately controlled at present.
  • History or current evidence of clinically significant cardiovascular or cerebrovascular disease, specifically including:

Myocardial infarction, unstable angina, or stroke within the past 6 months; Unstable or life-threatening arrhythmia requiring intervention within the past 3 months; New York Heart Association (NYHA) Functional Class III or IV heart failure.

  • Poorly controlled hypertension despite medication (systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg).
  • Poorly controlled type 2 diabetes mellitus (e.g., fasting blood glucose >10 mmol/L).
  • Planned surgery before the end of the study.
  • History of malignancy in any organ system within the past 5 years (except for non-metastatic basal cell or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix, with complete remission for >5 years prior to screening).
  • Clinically significant laboratory abnormalities at the screening visit (V1) as determined by the investigator, including alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2 × upper limit of normal (ULN), alkaline phosphatase >2 × ULN, or total bilirubin >1.5 × ULN.
  • Female subjects who are pregnant, breastfeeding, or planning to become pregnant during the study.
  • Any other condition considered by the investigator as unsuitable for participation in the study.

Cohort B:

  • History of life-threatening COPD (e.g., prior intensive care unit admission or requiring intubation).
  • Experienced a COPD exacerbation requiring systemic corticosteroids within 3 months prior to the screening visit (V1).
  • One or more hospitalizations due to COPD exacerbation or pneumonia within 3 months prior to screening.
  • Presence of other clinically significant respiratory diseases, as specified in Criterion A.2.
  • Chest computed tomography (CT) scan showing clinically significant abnormalities not attributable to COPD and judged by the investigator to potentially affect trial evaluation or subject safety.
  • Use of oral theophylline or its derivatives for COPD treatment within 1 week prior to the screening visit (V1).
  • Prior treatment with TQC3721.
  • Any other systemic disease deemed by the investigator to be clinically significant and not adequately controlled at present.
  • History or current evidence of clinically significant cardiovascular or cerebrovascular disease, as specified in Criteria A.4.
  • Poorly controlled hypertension, as specified in Criterion A.5.
  • Poorly controlled type 2 diabetes mellitus, as specified in Criterion A.6.
  • Major surgery (requiring general anesthesia) within 8 weeks prior to the screening visit (V1) with incomplete recovery, or planned surgery before the end of the study.
  • Clinically significant laboratory abnormalities at screening, as specified in Criterion A.9.
  • Requirement for long-term daily oxygen therapy (defined as cumulative use >12 hours per day).
  • Female subjects who are pregnant, breastfeeding, or planning to become pregnant during the study.
  • Participation in any other investigational drug or medical device clinical trial within 4 weeks prior to screening, or within 5 half-lives of the previous investigational agent (whichever is longer).
  • Any other condition considered by the investigator as unsuitable for participation in the study.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: TQC3721 Suspension for Inhalation (Twice a day)

Queue A: One TQC3721 suspension for inhalation (6mg/2ml), twice a day for 24 weeks.

Queue B: One TQC3721 suspension for inhalation (6mg/2ml), twice a day for 12 weeks.

TQC3721 suspension for inhalation is a Phosphodiesterase3/4 (PDE3/4) inhibitor.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Adverse event rate
Délai: Queue A: Extended study period: Weeks 24-50; Queue B: At week 12 of treatment

The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs).

Queue A: Extended study period: Weeks 24-50; Queue B: At week 12 of treatment
Number of subjects with laboratory abnormalities
Délai: Queue A: Extended study period: Weeks 24-50; Queue B: At week 12 of treatment

Number of subjects with laboratory tests showing abnormal results

Queue A: Extended study period: Weeks 24-50; Queue B: At week 12 of treatment
Change from baseline in trough Forced Expiratory Volume in 1 second (FEV₁)
Délai: At week 12 of treatment

Change in FEV₁ from baseline (pulmonary function at screening) at 12 weeks of treatment

At week 12 of treatment

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Annualized rate of moderate or severe COPD acute exacerbations
Délai: Up to 48 weeks

Annualized rate of moderate or severe Obstructive Chronic Pulmonary Disease (COPD) acute exacerbations over 48 weeks of treatment (compared according to the treatment groups in the TQC3721-III-01 study).

Up to 48 weeks
On-treatment time to first moderate or severe exacerbation
Délai: Up to 48 weeks

Time to first moderate or severe COPD exacerbation over the 48-week treatment period (To be compared according to the randomized treatment groups assigned in the TQC3721-III-01 study).

Up to 48 weeks
Change from baseline in trough Forced Expiratory Volume in 1 second (FEV₁)
Délai: At weeks 32, 40, and 48 of treatment

Analysis of change from baseline in trough FEV₁ at weeks 32, 40, and 48 of treatment (Baseline is defined as the corresponding value from the TQC3721-III-01 study; comparisons will be performed according to the randomized treatment groups assigned in that study).

At weeks 32, 40, and 48 of treatment

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

14 avril 2026

Achèvement primaire (Estimé)

1 février 2027

Achèvement de l'étude (Estimé)

1 novembre 2027

Dates d'inscription aux études

Première soumission

7 mars 2026

Première soumission répondant aux critères de contrôle qualité

7 mars 2026

Première publication (Réel)

11 mars 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

28 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

24 septembre 2026

Dernière vérification

1 mars 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • TQC3721-III-02

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .